HFMRX
Price
$26.16
Change
+$0.28 (+1.08%)
Updated
Jun 2 closing price
Net Assets
3.62B
PMBJX
Price
$36.06
Change
-$0.20 (-0.55%)
Updated
Jun 2 closing price
Net Assets
24.56B
Interact to see
Advertisement

HFMRX vs PMBJX

Header iconHFMRX vs PMBJX Comparison
Open Charts HFMRX vs PMBJXBanner chart's image
HFMRX vs PMBJX Comparison Chart in %
View a ticker or compare two or three
VS
HFMRX vs. PMBJX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HFMRX is a Buy and PMBJX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
PMBJX has more cash in the bank: 24.6B vs. HFMRX (3.62B). HFMRX (0.00) and PMBJX (0.00) have matching dividends . HFMRX was incepted earlier than PMBJX: HFMRX (17 years) vs PMBJX (25 years). HFMRX (1.48) is less costly to investors than PMBJX (0.76). HFMRX is a more actively managed with annual turnover of: 81.00 vs. PMBJX (13.70). HFMRX has a lower initial minimum investment than PMBJX: HFMRX (0) vs PMBJX (1000). HFMRX annual gain was more profitable for investors over the last year : -11.10 vs. PMBJX (-13.38). PMBJX return over 5 years is better than : -1.52 vs. HFMRX (-37.00).
HFMRXPMBJXHFMRX / PMBJX
Total Expense Ratio1.480.76195%
Annual Report Gross Expense Ratio1.480.76195%
Fund Existence17 years25 years-
Gain YTD8.421-6.906-122%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets3.62B24.6B15%
Annual Yield % from dividends0.000.00-
Returns for 1 year-11.10-13.3883%
Returns for 3 years-6.8715.44-45%
Returns for 5 years-37.00-1.522,442%
Returns for 10 years-4.4076.50-6%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MATV8.200.29
+3.67%
Mativ Holdings
CHSCL25.83-0.04
-0.15%
CHS
BTSG59.34-0.64
-1.07%
BrightSpring Health Services
TNET48.10-0.82
-1.68%
Trinet Group
MCRB7.33-0.31
-4.06%
Seres Therapeutics Inc